Terms: = Breast cancer AND TCF7L2, ENSG00000148737, 6934, TCF-4 AND Treatment
14 results:
1. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy.
Zhu Y; Tao LF; Liu JY; Wang YX; Huang H; Jiang YN; Qian WF
Cancer Med; 2023 Jul; 12(14):15704-15719. PubMed ID: 37306188
[TBL] [Abstract] [Full Text] [Related]
2. Development of a Novel Immune-Related Gene Prognostic Index for breast cancer.
Yao Y; Kong X; Liu R; Xu F; Liu G; Sun C
Front Immunol; 2022; 13():845093. PubMed ID: 35558081
[TBL] [Abstract] [Full Text] [Related]
3. The Wnt3a/β-catenin/tcf7l2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
[TBL] [Abstract] [Full Text] [Related]
4. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
Qiu N; He YF; Zhang SM; Zhan YT; Han GD; Jiang M; He WX; Zhou J; Liang HL; Ao X; Xia HM; Li J; Yang YY; He ZM; Zou ZZ; Li HS
Cancer Lett; 2019 Nov; 464():25-36. PubMed ID: 31461670
[TBL] [Abstract] [Full Text] [Related]
5. Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.
Gupta N; Srivastava SK
Mol Cancer Ther; 2019 Oct; 18(10):1708-1720. PubMed ID: 31270151
[TBL] [Abstract] [Full Text] [Related]
6. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
Mizugaki H; Hamada A; Shibata T; Hosoda F; Nakamura H; Okuma Y; Shukuya T; Umemura S; Horiike A; Fukui T; Kogure Y; Daga H; Urata Y; Yamada K; Saeki S; Fujisaka Y; Nakamura Y; Sato M; Yoshida T; Hotta T; Oizumi S; Fujiwara Y; Ohe Y; Fujiwara Y
Lung Cancer; 2019 Feb; 128():20-25. PubMed ID: 30642448
[TBL] [Abstract] [Full Text] [Related]
7. CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways.
Knutti N; Huber O; Friedrich K
Mol Cell Biochem; 2019 Jan; 451(1-2):197-209. PubMed ID: 30022447
[TBL] [Abstract] [Full Text] [Related]
8. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary breast cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
9. MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway.
Jiang Q; He M; Guan S; Ma M; Wu H; Yu Z; Jiang L; Wang Y; Zong X; Jin F; Wei M
Tumour Biol; 2016 Apr; 37(4):5001-11. PubMed ID: 26537584
[TBL] [Abstract] [Full Text] [Related]
10. Targeting beta-catenin signaling to induce apoptosis in human breast cancer cells by z-guggulsterone and Gugulipid extract of Ayurvedic medicine plant Commiphora mukul.
Jiang G; Xiao X; Zeng Y; Nagabhushanam K; Majeed M; Xiao D
BMC Complement Altern Med; 2013 Aug; 13():203. PubMed ID: 23914993
[TBL] [Abstract] [Full Text] [Related]
11. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
Ren Y; Zhou X; Qi Y; Li G; Mei M; Yao Z
Oncol Rep; 2012 Sep; 28(3):943-8. PubMed ID: 22710837
[TBL] [Abstract] [Full Text] [Related]
12. Effects of EpCAM overexpression on human breast cancer cell lines.
Gostner JM; Fong D; Wrulich OA; Lehne F; Zitt M; Hermann M; Krobitsch S; Martowicz A; Gastl G; Spizzo G
BMC Cancer; 2011 Jan; 11():45. PubMed ID: 21281469
[TBL] [Abstract] [Full Text] [Related]
13. Control of tcf-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines.
Beildeck ME; Islam M; Shah S; Welsh J; Byers SW
PLoS One; 2009 Nov; 4(11):e7872. PubMed ID: 19924301
[TBL] [Abstract] [Full Text] [Related]
14. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.
Mason CK; McFarlane S; Johnston PG; Crowe P; Erwin PJ; Domostoj MM; Campbell FC; Manaviazar S; Hale KJ; El-Tanani M
Mol Cancer Ther; 2008 Mar; 7(3):548-58. PubMed ID: 18347142
[TBL] [Abstract] [Full Text] [Related]
